New data show that using a liquid biopsy every three months to look for breast cancer tumor DNA enables detection of disease recurrence almost 11 months before it would otherwise be detected on imaging, exam or by symptoms.
Findings: This independent, prospective, multicenter, validation study of 101 women early-stage breast cancer assessed circulating tumor DNA mutation tracking and found that detection of circulating tumor DNA during follow-up had a median lead time of 10.7 months compared with clinical relapse, anticipating relapse in all major breast cancer subtypes. Brain-only metastasis was detected less frequently by circulating tumor DNA analysis, potentially requiring alternative surveillance.
Read the study: bit.ly/2YFV5GK
Viewing 1 post (of 1 total)
The forum ‘Breast Cancer’ is closed to new topics and replies.